Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195.
Cyrus Tang Hematology Center, Ministry of Education Engineering Center for Hematological Disease, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Prevention, Soochow University, Suzhou 215123, China.
Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12359-12367. doi: 10.1073/pnas.1918445117. Epub 2020 May 13.
Hepsin is a transmembrane serine protease primarily expressed in the liver. To date, the physiological function of hepsin remains poorly defined. Here we report that hepsin-deficient mice have low levels of blood glucose and lipids and liver glycogen, but increased adipose tissue browning and basal metabolic rates. The phenotype is caused by reduced hepatocyte growth factor activation and impaired Met signaling, resulting in decreased liver glucose and lipid metabolism and enhanced adipocyte browning. Hepsin-deficient mice exhibit marked resistance to high-fat diet-induced obesity, hyperglycemia, and hyperlipidemia. In mice, hepsin deficiency ameliorates obesity and diabetes. These data indicate that hepsin is a key regulator in liver metabolism and energy homeostasis, suggesting that hepsin could be a therapeutic target for treating obesity and diabetes.
hepsin 是一种主要在肝脏中表达的跨膜丝氨酸蛋白酶。迄今为止,hepsin 的生理功能仍未得到明确界定。在这里,我们报告称 hepsin 缺陷型小鼠的血糖和血脂及肝糖原水平较低,但脂肪组织褐变和基础代谢率增加。这种表型是由肝细胞生长因子激活减少和 Met 信号受损引起的,导致肝脏葡萄糖和脂质代谢减少,脂肪细胞褐变增强。hepsin 缺陷型小鼠对高脂肪饮食诱导的肥胖、高血糖和高血脂表现出明显的抵抗能力。在 肥胖小鼠中,hepsin 缺乏可改善肥胖和糖尿病。这些数据表明 hepsin 是肝脏代谢和能量平衡的关键调节剂,提示 hepsin 可能是治疗肥胖和糖尿病的治疗靶点。